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There is significant recent interest in Peto’s paradox and the related problem of
the evolution of large, long-lived organisms in terms of cancer robustness.
Peto’s paradox refers to the expectation that large, long-lived organisms
have a higher lifetime cancer risk, which is not the case: a paradox. This para-
dox, however, is circular: large, long-lived organisms are large and long-lived
because they are cancer robust. Lifetime risk, meanwhile, depends on the age
distributions of both cancer and competing risks: if cancer strikes before com-
peting risks, then lifetime risk is high; if not, not. Because no set of competing
risks is generally prevalent, it is instructive to temporarily dispose of compet-
ing risks and investigate the pure age dynamics of cancer under themultistage
model of carcinogenesis. In addition to augmenting earlier results, I show that
in terms of cancer-free lifespan large organisms reap greater benefits from an
increase in cellular cancer robustness than smaller organisms. Conversely, a
higher cellular cancer robustness renders cancer-free lifespan more resilient
to an increase in size. This interaction may be an important driver of the
evolution of large, cancer-robust organisms.
1. Introduction
Multicellularity is risky. Every cell could, in principle, escape the checks and bal-
ances of healthy organisms that keep individual cells from proliferating in an
uncontrolled manner and cause cancer [1–3]. To do so, a cell needs to differ in
a number of ways from normal cells (i.e. rate limiting stages or ‘hits’). This obser-
vation has given rise to the ‘multiple hit model’ or the ‘multistage theory of
cancer’ [4–8]. Every ‘hit’ is a way in which cancer cells necessarily differ from
normal cells. For instance, a cancer cell needs to sidestep the checkpoints in the
cell cycle. Most hits seem to result from DNA mutations, whereas epigenetic
mutationsmayalso play a role [9–11]. For brevity, I write ‘mutations’ and ‘stages’.
It has long been recognized that with c stages, the cancer hazard rate should
rise approximately as a power of c2 1with age, andmany cancers seem to have a
hazard function that is at least approximately compatible with this model [4].
If having many cells is risky, then having even more cells should be even
riskier. If the hazard rate increases with age as a power of c2 1, then a
longer life should progressively increase cancer risk. Hence, large, long-lived
organisms are expected to suffer a higher lifetime cancer risk than small,
short-lived organisms. This does not seem to be the case; an apparent contradic-
tion known as Peto’s paradox [12,13] that is receiving increasing attention from
the medical community [14,15].
Peto’s paradox [15–21], however, is circular. The paradox relies on assuming a
certain lifespan, after which the cancer risk during that lifetime is evaluated. This
seems thewrong procedure. Lifespan is a function, inter alia, of cancer robustness:
organisms are long-lived because they are cancer robust. If not, then theywould be
short-lived. One cannot next expect that they are not cancer robust and should
therefore have a higher lifetime cancer risk, based on the very same lifespan
that derives from high cancer robustness. Similarly, large organisms exist because
they are cancer robust; one cannot next expect that they are not.
Formulations like the following are equally uncomfortable: ‘the risk of
cancer should be many orders of magnitude greater in humans [than in
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mice]’ [17]. Lifetime cancer risk in mice is at least one-third
[22,23], so lifetime cancer risk in humans cannot possibly
be orders of magnitude higher.
To give another example, Peto mentions the rapid
increase with age of cancer risk up to that age, the implica-
tion being that a longer life leads to a progressively higher
lifetime cancer risk [12]. Apart from the objection to this
procedure raised above, a steeper increase of the cancer inci-
dence rate (and risk) with age actually reduces cancer risk
up to any specified age, cancer being postponed to later
ages (figure 1).
Clearly, the conceptualization of these matters in terms of
lifetime risk invites unsound reasoning. In addition, lifetime
risk does not reveal whether organisms die at age 1, or at
age 100. Without other causes of death, ‘competing risks’ in
the epidemiological literature [24–26], lifetime cancer risk is
1. With competing risks, lifetime cancer risk depends entirely
on the way age distributions of cancer and competing risks
interact. Hence, a lifetime risk is always situational: it is
true only in the context of a specific set of competing risks.
A recent paper has investigated lifespan extension as a
result of a change in cancer dynamics, exploring a theoretical
model of cancer in the presence of a specific competing risk in
the form of constant ‘extrinsic mortality’ [27]. Thus, organ-
isms die of either cancer or ‘extrinsic mortality’, whichever
strikes first, and overall lifespan is calculated. This approach
overcomes the problems related to lifetime cancer risk, but
the reported results hold only under a constant competing
risk hazard. For instance, a constant ‘extrinsic mortality’
rate of 0.1 per year implies that overall lifespan cannot be
extended beyond 1/0.1 ¼ 10 years, regardless of cancer
dynamics. But there are various non-cancer mortality func-
tions other than a constant mortality rate of 0.1 that limit
lifespan at 10, for instance the Gompertz function aebx with
a ¼ 0.001 and b ¼ 0.579701. The perturbation that Kokko &
Hochberg [27] report to result in a lifespan reduction from
9.40 to 7.79 (their figure 1d ) then instead yields a lifespan
reduction from 9.99 to 9.74: a significantly different result.
Because there is no generally prevalent set of competing
risks, it is instructive to temporarily dispose of competing
risks and investigate the pure age dynamics of cancer:
cancer-free lifespan, its coefficient of variation and its
sensitivity to model parameters. Here, I show how such a
theory could take shape, how earlier results can be augmen-
ted and how new exciting results can be obtained along these
lines. I analyse a straightforward model of cancer age inci-
dence under the multistage model of carcinogenesis that is
a slightly adapted version of the Calabrese–Shibata model
[28] also analysed in various recent papers [16,27,29]. Yet it
can be analysed even deeper, with surprising results: in
terms of cancer-free lifespan, large organisms reap greater
benefits from an increase in cellular cancer robustness than
smaller organisms. Reversely, a higher cellular cancer robust-
ness renders cancer-free lifespan more resilient to an increase
in size. This interaction may be an important driver of the
evolution of large, cancer-robust organisms.
The model [28] is the most direct derivation of cancer age
incidence under the multistage model of carcinogenesis,
making it fundamental to cancer research. Achieving a good
understanding of the model dynamics is therefore of consider-
able interest. It should be emphasized, however, that various
biological factors that influence carcinogenesis are not in the
model, such as clonal expansion, selection and varying
mutation rates, making the predictions inexact at best. Never-
theless, the model does chart the basic machinations of a
process that iswidely believed to be fundamental to carcinogen-
esis, and it serveswell tohighlight important theoretical aspects.
2. Model analysis
Suppose that cancer requires c mutations, stages. Suppose
that an organism consists of s potentially malignant cells.
Further suppose that genes mutate at a per time rate m. Let
Z denote the time to mutation of an individual gene. The
probability that Z exceeds x, so that the gene is not mutated
at age x, is then
PðZ . xÞ ¼ e
Ð x
0
mðtÞdt
: ð2:1Þ
With constant m, this gives
PðZ . xÞ ¼ emx, ð2:2Þ
but the original equation may be used for more involved
modelling [4].
Let Y denote the healthy survival time of an individual
cell, which ends if c mutations have occurred;
PðY . xÞ ¼ 1 ð1 emxÞc: ð2:3Þ
Let X denote the healthy survival time of an entire organ-
ism. For an organism to be cancer-free, all cells need to be
cancer-free. For s cells, the cancer-free survivorship up to
age x for the entire organism is
PðX . xÞ ¼ lðxÞ ¼ ð1 ð1 emxÞcÞs: ð2:4Þ
Equation (2.4) is the same as the equation originally derived
by Calabrese & Shibata [28], only now in continuous time
rather than in ‘cell division time’ and for an entire organism
rather than for the bowel alone. The same equation (or
similar) is found in [16,27,29].
To explore age patterns, probability density function f (x)
is calculated as
f ðxÞ ¼  d
dx
lðxÞ
¼ mcsemxð1 emxÞc1ð1 ð1 emxÞcÞs1: ð2:5Þ
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Figure 1. The hazard rate as a function of age for several parameter settings.
The black line is the reference model. The number of mutations that gives
cancer, c, changes the shape of the hazard rate (dark blue line). The
number of cells at risk, s, scales the hazard rate (grey line). Mutation rate
m gives the accelerated failure time effect (light blue line). Note that the
plateau is not reached during normal lifespan. (Online version in colour.)
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Change in survivorship f (x) comes down on those organisms
still alive (i.e. cancer-free), expressed by the hazard rate l(x),
lðxÞ ¼ fðxÞ
lðxÞ ¼ mcse
mx ð1 emxÞc1
ð1 ð1 emxÞÞc : ð2:6Þ
The total number of stem cells in humans seems to be in the
order of 1011 [10], but organisms like elephants and whales are
clearly expected to have many more. I follow earlier work
[16,27] in taking a yearly mutation rate of m ¼ 0.00027375.
The number of mutations necessary for cancer may be as low
as two [7] or three [30], but is thought to be typically higher,
in the range of 3–8. I explore a wide range of parameter
values as appropriate.
It was recognized long ago [4] that with c stages the
hazard rate should increase by a power of c2 1 with age.
However, this is true only initially. The population increas-
ingly consists of organisms of s cells waiting for their last
mutation (all other organisms already have cancer), which
comes at mutation rate m, meaning that the hazard rate
limits at sm. This explains why the hazard rate increases
faster with age in relative terms for larger c (initially increas-
ing as a power of c2 1 with age), whereas one would expect,
c being a cancer-robustness mechanism, that the hazard rate
would be higher for smaller c than for larger c at all ages.
Through the limit at ms, such is, indeed, the case (figure 1).
The hazard rate is helpful in charting the effects of par-
ameter changes (figure 1 and equation (2.6)). Multiplication
of s by some factor f. 0 multiplies the hazard rate by f
for all ages: s scales the hazard rate, which means it gives a
proportional hazards model [31]. A change in c does not
change the level of the plateau, but changes the way the
curve approaches the plateau. If c is higher, the hazard rate
stays lower for longer, but eventually catches up. Finally, m
not only scales the hazard rate, but also its time dimension:
multiplying m by some f. 0 changes l(x) to fl(fx) and
f (x) to ff(fx) (equations (2.6) and (2.5)), whereas the same
survivorship would be reached at x/f (equation (2.4)). This
model is known as the accelerated failure time model [31],
which means that a straightforward relationship exists
between m and survivorship: the distance between any two
points is multiplied by 1/f in the age dimension, but
except for this scaling the survivorship function is identical.
Cancer-free lifespan, calculated as the first moment around
0 of f(x), or as the sum under the survivorship curve [31], is key
in any framework of analysis. The accelerated failure time
property of m means that multiplication of m by f amounts
to multiplying cancer-free lifespan by 1/f, with no surprising
effects. For parameters c and s, effects are shown in figure 2:
organisms that are orders of magnitude larger (high s) need
only a slightly higher number of stages (higher c) to achieve
the same cancer-free lifespan. In addition, figure 2 suggests
that this effect is stronger the larger s is.
The interaction between c and s is further explored in figure 3.
Figure 3a shows a heatmap of cancer-free lifespan after an
increase in c as a percentage of cancer-free lifespan before that
increase while keeping s constant. Figure 3b shows a heat map
of cancer-free lifespan after an increase in s as a percentage of
cancer-free lifespan before that increasewhile keeping c constant.
For an increase in c, these percentages are greater than 100,
because increasing c increases cancer-free lifespan. For an
increase in s, these percentages are smaller than 100, because
increasing s decreases cancer-free lifespan. Significantly, the
effect on cancer-free lifespan following an increase in s is smaller
when c is larger,whereas the effect on cancer-free lifespan follow-
ing an increase in c is largerwhen s is larger.Hence, the larger the
organism, the more it gains from an increase in c, whereas the
higher c, the smaller the proportional reduction in cancer-free
lifespan following an increase in s. A similar interaction between
c and s occurs for their effectiveness in reducing the coefficient of
variation (electronic supplementary material, figure S1).
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Figure 2. Cancer-free lifespan for several parameter settings. Mutation rate m is fixed at m ¼ 0.00027375, because the effect of m is described entirely by the
accelerated failure time model. The number of stages, c, and the number of cells at risk, s, seem to interact. Compare for instance the change from c ¼ 6 to c ¼ 8
for s ¼ 100 increasing 10-fold to s ¼ 1000 versus the same change in c for s ¼ 1010 increasing 10-fold to s ¼ 1011. In the first case, the original lifespan is not
recovered. In the second case, the original cancer-free lifespan is more than doubled. Note that the step size for s is multiplicative, while being additive for c.
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3. Discussion
The findings in this paper demonstrate the benefits of cancer-free
survivorship rather than lifetime cancer risk as themetric of inter-
est in investigations regarding the evolution of cancer. This
perspective was used to rethink Peto’s paradox, which was
found to be circular. Large, long-lived animals can exist if and
only if they are cancer robust; one cannot next expect them to
have a higher lifetime cancer risk because they are not cancer
robust. Theobservation that (cells of) large, long-livedorganisms
must be more cancer robust than (those of) small, short-lived
organisms is shrewd and of great importance, but should have
been the endpoint. The expectation that large, long-lived animals
should have a higher lifetime cancer risk than small, short-lived
organisms is anunnecessaryand faultyextra step, as is the result-
ing paradox when that prediction remains unconfirmed. Given
that whales live up to 200 years and weigh up to 200 000 kg
[32], their cancer dynamics differ from those of humans, and
the ‘promise of comparative oncology’ [17] stands.
The relevance of the age distribution of cancer and compet-
ing risks has not gone unnoted. Various authors have noted
that postponing cancer until after reproduction renders natural
selection largely powerless in cancer suppression [12,29,33,34].
Lichtenstein [35] commented on the timing of cancer from the
perspective of Peto’s paradox: ‘animals with a small body
weight and short lifespan (e.g. rodents) should not suffer from
cancer at all, while big animals (whales) should get cancer in
their mothers’ wombs’. Noble et al. [18] mention both age distri-
butions and competing risk in their reanalysis of Tomasetti &
Vogelstein [10], as do Caulin et al. [16]. In several life-history
models of cancer, competing risks (and hence necessarily age
distributions) feature prominently [20,27,29]. Yet these papers
have stopped short of disposing of Peto’s paradox and placing
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Figure 3. Cancer-free lifespan as a percentage of old lifespan (a) following a step increase in c while keeping s constant, and (b) following a step increase in s while
keeping c constant. For example, for an organism characterized s ¼ 106, c ¼ 5, an increase in c from 5 to 6 would result in an increase in cancer-free lifespan by
a factor of 1.63, whereas an increase in s from 106 to 107 would result in a decrease in cancer-free lifespan by a factor of 0.62 (m ¼ 0.00027375).
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cancer-free survivorship (rather than lifetime risk) at the heart of
the theory, whereas the use of a specific set of competing risks
limits thegeneralityof the results. Lifetime riskoroverall lifespan
can certainly be calculated if one is interested in a specific set of
competing risks, but keeping in mind that the results are
restricted to situations where that set of competing risks applies.
A greater number of stages has been suggested before as a
possible mechanism by which larger organisms can protect
themselves against cancer [16,21,34,36]. Caulin et al. [16]
found that ‘increasing the number of hits required for cancer
was a powerful tumour suppressive mechanism’. This result
presaged the findings here (figure 2), with the reservations
that the effect of c depends on s, and that Caulin et al. look at
cancer risk before age 90, subject to all the objections raised
above, rather than cancer-free survivorship.
Caulin et al. [16] when exploring lifetime cancer risk in the
Calabrese–Shibata model found that a 3.2-fold reduction in
the mutation rate compensates for a 1000-fold increase in
body size. This claim is at odds with the findings of others
[27,29], who find that a doubling of m halves cancer-free
survivorship up to any point. The identification of the
effect of m with the accelerated failure time model confirms
the results of [27] and [29], whereas the finding of Caulin
et al. [16] seems an artefact of their parameter settings
(electronic supplementary material, figure S2).
Kokko & Hochberg [27] call for mathematical models that
explore how c and s co-evolve. They find that larger organisms
gain more from an increase in c from 3 to 4 than smaller organ-
isms (their figure 2c). They do not, however, show the
dependence of the effect of a change in s on c, do not discuss
the coevolution of c and s, and as noted their results depend
on the specific, non-general set of competing risks that they con-
sider, to wit age-invariant ‘extrinsic mortality’. Kokko &
Hochberg [27] further write that reducing m (their parameter
k) has an effect similar to increasing c (their parameter n). The
above-mentioned analysis shows that m gives the accelerated
failure time model, with no interactions with other model par-
ameters, whereas the effect of c is not that of the accelerated
failure time model, depending instead on s and on c itself.
While both m and c could be manipulated to postpone cancer,
these manipulations work out differently.
Finally, Brown et al. [20] make the ‘assumption of dimi-
nishing returns to increased cancer suppression’, which is
corroborated by the finding in this paper that a further increase
in c becomes less beneficial the larger c is (but becomes more
beneficial again following an increase in s).
The favourable interaction between c and smay be of para-
mount evolutionary importance: organismsmaydifferorders of
magnitude in body size, but to equalize their cancer-free life-
spans requires only a small number of additional cancer
robustness mechanisms in the larger organism. This is effective
especially if organisms are large. It would be interesting if experts
in cellular biology could comment onhow they view the costs of
reducing m versus increasing c in organisms of different sizes.
Because extra robustnessmechanisms (high c) aremore effective
in larger organisms (high s), larger organisms could let
mutations run relatively free (high m) as long as they assure
some extra robustness in terms of high c. How does this weigh
against the conflicting but equally reasonable hypothesis that
mutation rates in larger organisms must be lower to protect
them against cancer [21]? In addition, the reduction in variabil-
ity as measured by the coefficient of variation could have
evolutionary advantages, as it brings predictability to the life
cycle. If the same life expectancy is reached through two differ-
ent combinations of c and s, say (c1, s1) and (c2, s2) with c1. c2
and s1. s2, then (c1, s1) will have a more predictable life cycle
than (c2, s2). For these reasons, mutually reinforcing effects of c
and s uncovered here could be a major driver of the evolution
of large, cancer-robust organisms.
A model is useful when it approximates reality. The model
analysed here forms a good approximation of any cancer
formation process that requires multiple discrete stages that are
acquired at approximately constant rates over age. This model
has been criticized [37], and the mathematical model explored
here leaves out important biological factors that affect oncogen-
esis, such as clonal expansion, ageing, selection and varying
mutation rates. There exist several ways in which the model
couldbemademore involved.Non-stemcells couldbemodelled
to havemore stages than stem cells, as they aremore phenotypi-
cally different from cancer cells, which could be modelled as
subpopulations of cells with different c, c being higher for non-
stem cells. Furthermore, mutations could increase the mutation
rate itself, giving rise to the ‘mutatorphenotype’ [38]. Eventually,
tumours become complex adaptive systems, made up of a het-
erogeneous population of cells that compete, interact with their
environment and undergo evolution by natural selection
[9,33,39]. Nevertheless, it remains true that a number of modifi-
cations is required before cells become malignant [40] and the
multistage model remains of interest [9,41].
Restricted to the basic logic of the multistage model of car-
cinogenesis, equations (2.2)–(2.4) describe not just a simple
model; they describe the simplest model possible. Equation (2.2)
is the general expression of survivorship as a function of a con-
stant mortality rate (in this case, a gene remaining unmutated
as a function of a constant mutation rate). Equations (2.3) and
(2.4) then result from basic probability theory, and the density
function and rate immediately follow from standard survival
analysis. Therefore, for all its flaws and inaccuracies, the
model analysed here represents the simplest case and serves
well to demonstrate the theoretical points addressed in this
paper. Perhaps more involved, more realistic models could
build on these insights.
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